Leap Therapeutics Inc. (LPTX) has several pivotal clinical trial milestones to watch for in the coming months, particularly regarding its lead drug candidate, DKN-01, an anti-DKK1 monoclonal antibody.
DKN-01 is being tested in combination with standard therapies for advanced colorectal and gastric cancers. A phase II trial evaluating DKN-01 in combination with bevacizumab and chemotherapy for second-line treatment of advanced colorectal cancer, dubbed DeFianCe, is underway. Enrollment in the expanded randomized controlled Part B of the DeFianCe study has been completed, with initial results expected in mid-2025.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.